Validation of CRP as prognostic marker for renal cell carcinoma in a large series of patients. - Wikidata - awgldk - TriplyDB

Validation of CRP as prognostic marker for renal cell carcinoma in a large series of patients.

Validation of CRP as prognostic marker for renal cell carcinoma in a large series of patients.

http://www.wikidata.org/entity/Q34408625

about

Prognostic Value of Neutrophil-to-Lymphocyte Ratio in Localized and Advanced Prostate Cancer: A Systematic Review and Meta-Analysis C-Reactive Protein Is an Important Biomarker for Prognosis Tumor Recurrence and Treatment Response in Adult Solid Tumors: A Systematic Review Pretreatment Neutrophil to Lymphocyte Ratio as a Prognostic Predictor of Urologic Tumors: A Systematic Review and Meta-Analysis Serum and urine biomarkers for human renal cell carcinoma Complex pattern of interleukin-11-induced inflammation revealed by mathematically modeling the dynamics of C-reactive protein.Post-treatment neutrophil-to-lymphocyte ratio in predicting prognosis in patients with metastatic clear cell renal cell carcinoma receiving sunitinib as first line therapy.Preoperative serum C- reactive protein: a prognostic marker in patients with upper urinary tract urothelial carcinoma High CRP values predict poor survival in patients with penile cancer.Elevated C-reactive protein values predict nodal metastasis in patients with penile cancer C-reactive protein as a prognostic factor for human osteosarcoma: a meta-analysis and literature review.Prognostic significance of pre-operative C-reactive protein and the neutrophil-lymphocyte ratio in resectable pancreatic cancer: a systematic review Is C-reactive protein useful in prognostication for colorectal cancer? A systematic review.Prognostic Role of C-Reactive Protein In Urological Cancers: A Meta-Analysis The C-reactive protein/albumin ratio, a validated prognostic score, predicts outcome of surgical renal cell carcinoma patients The prognostic utility of preoperative neutrophil-to-lymphocyte ratio in localized clear cell renal cell carcinoma.Pre-treatment neutrophil-to-lymphocyte ratio may be associated with the outcome in patients treated with everolimus for metastatic renal cell carcinoma Roles of preoperative C-reactive protein are more relevant in buccal cancer than other subsites.Neutrophil-lymphocyte ratio in small renal masses.Metastasectomy for metastatic renal cell carcinoma in the era of modern systemic treatment: C-reactive protein is an independent predictor of overall survival.Critical evaluation of the potential prognostic value of the pretreatment-derived neutrophil-lymphocyte ratio under consideration of C-reactive protein levels in clear cell renal cell carcinoma.Do preoperative serum C-reactive protein levels predict the definitive pathological stage in patients with clinically localized prostate cancer?Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapy.Nomograms incorporating serum C-reactive protein effectively predict mortality before and after surgical treatment of renal cell carcinoma.The impact of elevated C-reactive protein level on the prognosis for oro-hypopharynx cancer patients treated with radiotherapy.Prognostic significance of pre-operative inflammatory markers in resected gallbladder cancer: a systematic review.Can preoperative neutrophil lymphocyte ratio predict malignancy in patients undergoing partial nephrectomy because of renal mass?Editorial Comment to Metastasectomy for metastatic renal cell carcinoma in the era of modern systemic treatment: C-reactive protein is an independent predictor of overall survival.Prognostic value of preoperative NLR, dNLR, PLR and CRP in surgical renal cell carcinoma patients.The Predictive Value of Inflammation-Related Peripheral Blood Measurements in Cancer Staging and Prognosis.C-Reactive protein: a major inflammatory biomarker Preoperative butyrylcholinesterase level as an independent predictor of overall survival in clear cell renal cell carcinoma patients treated with nephrectomy

P2860

Q26751553-F0D7B158-2385-4B32-8C27-9EE10CE24722 Q26771557-972A2A1A-4FC4-4D3A-8C80-22B0F296445E Q26786160-DF200C17-413A-4636-AFEB-6F2DF9784BBD Q28084949-5F7751DB-86BF-4FCB-BC2C-035D8FC01D9D Q33417707-E92C8E87-85C7-40DF-867F-7E9398785643 Q33655475-366A11E2-1CC7-46A5-BDBF-69D59A24819E Q34623313-4444836E-7BBA-49CB-8C65-7817C350F5AA Q34705218-2E7E6A8E-0631-4E67-8507-F97428270A35 Q35024082-1961BE36-3B2A-4FC9-9F09-D479F368525E Q35163616-EF1B8D24-0454-4253-9C6A-85BA74EB743C Q35202177-EF3F168C-7F28-48EA-A38B-EC1480014956 Q35209326-C677504F-D1AB-483E-AC63-1B76C7F94D9D Q35909777-26406B1F-F349-4F46-81B9-E0E1F92E0A53 Q36298727-F4FBE0DE-661F-4A0F-99AA-204D9332D234 Q36784093-E79FA4F6-47D9-4BAF-B21E-84378A2C9EE3 Q37214300-C3345637-5486-442A-8434-207F019FDEB4 Q37649049-26021F38-9F97-46D9-A392-A415BE2F4B16 Q37679644-B8213D8C-99CA-42EB-A0EE-67A6C9516160 Q38805775-7039EF8D-032A-4BA2-A0EF-5C2843242D4A Q39138898-B9C32BFC-4990-4E90-96CE-9EFA795D720B Q40264726-8BD144F7-9A10-408B-AE27-E618B53BF615 Q41624982-9AC20FA7-4A00-4A08-B5AD-7BC4CDEB1793 Q46125956-F866A238-8557-48D8-B4D3-7C34EB9E2F40 Q47273007-1AA52B62-376D-4B3A-8E89-9C76ED5EC576 Q47330202-0AEE4952-6C50-4FB7-ACB5-E2B5EF2DB2A3 Q50050944-DDDF1AEA-E477-43BA-B6AF-8EF75F218AC5 Q51559518-2CAF3FBB-EC19-480A-B644-752BB05F905C Q51723701-4EB8A98A-4A4C-42B1-9589-37BE070788DD Q52605888-1FD5990F-B78E-4508-BB34-08A934A3E69C Q57818432-A22EA23E-C36E-4BD2-98DC-5541A3739B88 Q59101351-A1D08E7F-04B5-41B3-AD35-A0DB2D156B72

P2860

Validation of CRP as prognostic marker for renal cell carcinoma in a large series of patients.

http://www.wikidata.org/entity/Q34408625

description

2012 nî lūn-bûn

@nan

2012 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Validation of CRP as prognosti ...... in a large series of patients.

@ast

Validation of CRP as prognosti ...... in a large series of patients.

@en

Validation of CRP as prognosti ...... in a large series of patients.

@nl

type

label

Validation of CRP as prognosti ...... in a large series of patients.

@ast

Validation of CRP as prognosti ...... in a large series of patients.

@en

Validation of CRP as prognosti ...... in a large series of patients.

@nl

prefLabel

Validation of CRP as prognosti ...... in a large series of patients.

@ast

Validation of CRP as prognosti ...... in a large series of patients.

@en

Validation of CRP as prognosti ...... in a large series of patients.

@nl

P1433

Q34408625-A9C09EAF-6B90-498D-9906-F73194AEC631

P1476

Q34408625-12A1E671-43CB-4BB7-9188-E399762E9ED6

P2093

Q34408625-0032400F-4745-476E-B130-706F39BF7C85

Q34408625-29A2C48D-9C8E-441C-95CB-ADBC12689D77

Q34408625-2FC67A63-0445-4ADF-8B6D-9D2E0CB24CA6

Q34408625-3EF318ED-6322-4BDB-8873-DFAB34403D01

Q34408625-566410E3-7479-45F8-89E4-59EBA01991F8

Q34408625-97E69CF5-2EC4-4E1B-8330-CCA1DAC3C3F8

Q34408625-9DE4043D-3683-4A9F-8CD2-7C70CAA2789F

Q34408625-E6541E83-CE16-4EFA-BB07-4C9EF5D17B16

Q34408625-E9E1E8ED-2E16-459E-AD27-C92E33307F93

Q34408625-FABFECB1-C904-446F-B2D5-CADB36AE3F35

P2860

Q34408625-24C9BB60-E0DB-4091-962C-E84304D57A28

Q34408625-2EDC9BCF-74CB-4782-9F11-15620A9302BF

Q34408625-6121EDC4-D9BD-49F1-A8D4-53C84143104B

Q34408625-69FFAEBA-21CA-4FCB-AAA4-41E0FD06958C

Q34408625-73C698C1-9318-4CC2-846B-89856B78CF38

Q34408625-75F12D79-F12D-4461-818E-23BF0BAB97A6

Q34408625-96864975-80FD-46D5-BEEF-EB9F847499F6

Q34408625-970D7EC4-EDD5-4893-AAA7-B75A28D28E8B

Q34408625-A1732DFB-1A48-4421-97BD-74F83ADF167B

Q34408625-A74C3BD3-28DF-4EB6-8BD8-D4A062AC9EAD

P2888

Q34408625-34D92294-301A-48AF-8774-7FD2A2064CBC

P304

Q34408625-35F95C6E-5C1D-48F3-B583-762A9ED4FBC7

P31

Q34408625-5F10CFE0-C89A-4E73-BE4B-609C9DC0A269

P356

Q34408625-F82D32F5-0A45-41E3-9086-E02B4528B22E

P407

Q34408625-0DB84C72-9722-469E-8EFC-464D0A9A2643

P478

Q34408625-EA5590B0-D399-46E9-84E9-A8EC737CBBC6

P577

Q34408625-03D62873-9BE5-4DC5-80F6-BC4CDEC10F48

P5875

Q34408625-DB558C0F-70F3-414A-BFCE-FBBAFB458AEF

P6179

Q34408625-BDA0EE69-7810-490C-A915-F73C5ED3338A

P698

Q34408625-FB60B961-D32E-44D2-8E0E-CFD029E92227

P932

Q34408625-D3530B44-0B8A-431E-A1EF-A9060A74C178

P356

1471-2407-12-399

P1433

P1476

Validation of CRP as prognosti ...... in a large series of patients.

@en

P2093

Andres J Schrader

http://www.w3.org/2001/XMLSchema#string

Astrid Köhler

http://www.w3.org/2001/XMLSchema#string

Christoph Seidel

http://www.w3.org/2001/XMLSchema#string

Gerd Wegener

http://www.w3.org/2001/XMLSchema#string

Hendrik Eggers

http://www.w3.org/2001/XMLSchema#string

Mark Schrader

http://www.w3.org/2001/XMLSchema#string

Markus A Kuczyk

http://www.w3.org/2001/XMLSchema#string

Martin Janssen

http://www.w3.org/2001/XMLSchema#string

Raphael Rudolph

http://www.w3.org/2001/XMLSchema#string

Sandra Steffens

http://www.w3.org/2001/XMLSchema#string

P2860

Renal-cell carcinoma.

The systemic inflammatory response, performance status and survival in patients undergoing alpha-interferon treatment for advanced renal cancer.

A systematic review of the association between circulating concentrations of C reactive protein and cancer

Biomarkers in clear cell renal cell carcinoma.

Predicting disease progression after nephrectomy for localized renal cell carcinoma: the utility of prognostic models and molecular biomarkers.

Metastatic renal carcinoma comprehensive prognostic system

Management of distant solitary recurrence in the patient with renal cancer. Contralateral kidney and other sites.

Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma.

Interleukin-6 and renal cell cancer: production, regulation, and growth effects.

The impact of preoperative serum C-reactive protein on the prognosis of patients with upper urinary tract urothelial carcinoma treated surgically.

P2888

1471-2407-12-399

P304

399

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1471-2407-12-399

http://www.w3.org/2001/XMLSchema#string

P407

P478

12

http://www.w3.org/2001/XMLSchema#string

P577

2012-09-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

230835700

http://www.w3.org/2001/XMLSchema#string

P6179

1045313474

http://www.w3.org/2001/XMLSchema#string

P698

22958305

http://www.w3.org/2001/XMLSchema#string

P932

3502607

http://www.w3.org/2001/XMLSchema#string